PROM1 and non-small cell lung carcinoma: Similarly, CD133+ NSCLS cells were substantially more efficient at producing xenograft in NOD/SCID mice [24]; in NOD/SCID/IL2Rγ−/− mice, CD133+ and CD133− NSCLC cells generated xenografts at rates of 6/11 and 7/13, respectively [155].